Alexion exec to become AstraZeneca's CFO on closing of $39 billion acquisition
AstraZeneca PLC has appointed Dr. Aradhana Sarin as an executive director and chief financial officer conditional upon closing of AstraZeneca ’s acquisition of Boston-based Alexion Pharmaceuticals, Inc., where she is currently executive vice president and CFO.
Astra Zeneca in December agreed to purchase Alexion, a global rare diseases biopharmaceutical company, for $39 billion in cash and stock. The sale is expected to close in the th ird quarter of 2021.
Sarin will relocate from the United States…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Anne Stych Source Type: news
More News: AstraZeneca | Health Management | Mergers and Aquisitions | Pharmaceuticals | Rare Diseases